Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : PharmaLogic
Deal Size : Undisclosed
Deal Type : Agreement
ARTBIO and PharmaLogic Announce Supply Agreement for AB001
Details : PharmaLogic will assist ARTBIO with radiochemistry and supply finished radiopharmaceutical products for future Phase I and II clinical trials of AB001 (212Pb-NG001).
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
December 01, 2024
Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : PharmaLogic
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : 3B Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
ARTBIO and 3B Partner for Alpha Radioligand Therapy in Solid Tumors
Details : The agreement aims to develop an advanced preclinical stage first-in-class peptide 212Pb-based alpha radioligand therapies, for the treatment of solid tumors.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 13, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : 3B Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : SpectronRx
Deal Size : Undisclosed
Deal Type : Partnership
SpectronRx and ARTBIO Collaborate to Develop Clinical Supply of AB001
Details : The partnership aims to produce a novel prostate cancer therapy known as AB001 (212Pb-NG001), a promising therapy for prostate cancer, by utilizing SpectronRx's expertise and facilities.
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
September 01, 2024
Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : SpectronRx
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Study Phase : Phase I
Recipient : Nucleus RadioPharma
Deal Size : Undisclosed
Deal Type : Collaboration
ARTBIOS and Nucleus RadioPharma Collaborate for GMP-Grade Therapeutics with Pb-212
Details : Under the agreement, Nucleus will manufacture ARTBIO's 212Pb-radiolabeled therapies for Phase I and II trials in prostate cancer, using ARTBIO’s AlphaDirect™ 212Pb isolation technology.
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
July 05, 2024
Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Highest Development Status : Phase I
Recipient : Nucleus RadioPharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery Platform
Sponsor : Parabilis Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
FogPharma and ARTBIO Collaborate on Alpha-Particle Radioligand Therapies
Details : The collaboration aims to co-develop Helicon-enabled 212Pb alpha radioligand therapies by leveraging FogPharma’s field-leading Helicon platform and ARTBIO’s AlphaDirect™ platform, for cancer.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
May 14, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Sponsor : Parabilis Medicines
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The proceeds will be used to help solidify ARTBIO's proprietary Pb212 isolation technology AlphaDirect™ and its distributed manufacturing network, advance its lead program AB001 (212Pb-NG001) in the clinic for treatment of prostate cancer, and further ...
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : F-Prime Capital
Deal Size : $23.0 million
Deal Type : Financing
Details : The financing enables ARTBIO's ongoing clinical development of its lead program AB001 (212Pb-NG001) for the treatment of prostate cancer and will advance its AlphaDirect™ Pb212 isolation technology.
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Undisclosed
June 21, 2023
Lead Product(s) : 212-Pb NG001
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : F-Prime Capital
Deal Size : $23.0 million
Deal Type : Financing
Phase 0/1 Study of 212Pb-NG001 in mCRPC
Details : Undisclosed
Product Name : Undisclosed
Product Type : Radiolabeled Compounds
Upfront Cash : Inapplicable
February 13, 2023